Related Experiment Videos

Paclitaxel and cisplatin in ovarian cancer

V Torri, P G Harper, N Colombo

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|June 1, 2000

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Multimodal tumor-agnostic ctDNA analysis for minimal residual disease detection and risk stratification in ovarian cancer: results from the MITO16a/MaNGO-OV2 trial.

ESMO open·2026

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025

PARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.

ESMO open·2025

Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.

European journal of cancer (Oxford, England : 1990)·2025

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

See all related articles